Dehong Capital Completes Exclusive Strategic Investment in Meihua Medical

(Beijing, Hong Kong, June 20, 2022) Today, Dehong Capital (DCP) announced that it has completed an exclusive strategic investment in Shanghai Meihua Medical Investment Management Co., Ltd. (hereinafter referred to as “Meihua Medical” or the “Company”). . After the transaction is completed, Dehong Capital will join hands with the Meihua Medical team to jointly promote the company’s endogenous and external growth, so as to consolidate its leading position in the core market of Shanghai.

Founded in 2003, Meihua Medical is a leading private medical service organization in Shanghai. It has two brands, “Meihua Medical” and “World Medical”, and three medical institutions. The company has always adhered to the core concept of customer-centricity, and is committed to providing high-quality, warm medical services. Since its establishment 19 years ago, Meihua Medical has served more than 100,000 families and guests, accumulated an excellent reputation, and laid a good foundation for development. The company is the first private women’s and children’s medical institution in Asia to be certified by the international certification organization DNV International Accreditation, which reflects the ability of Meihua Medical to provide customers with international high-level services while ensuring medical safety.

As the core market of Meihua Medical, Shanghai has the largest middle-class group in China and a huge demand for differentiated and high-quality medical services. In the post-epidemic era, the long-term rigid demand for high-quality medical services by the majority of customer groups will still drive the industry to show stable and sustained growth. As a leading company in the industry, Meihua Medical, which has experienced the test of the epidemic, will be able to better grasp the opportunities for industry growth and integration, achieve rapid development, and bring high-quality medical services to more customers.

Mr. Wang Wei, Managing Director of Dehong Capital, said: “Dehong Capital’s strategic investment in Meihua Medical is not only firmly optimistic about the long-term development potential of the medical service industry, but also highly recognized the Meihua Medical brand and the excellent medical care and management behind the brand. Team. We will continue to use our resources and network to empower Meihua Medical, fully promote the further development and growth of Meihua Medical’s business, and consolidate its leading position in the market.”

Mr. Ju Anshen, Managing Director of Dehong Capital, said: “Meihua Medical is another major investment we have made in the field of medical services. We will also fully grasp the opportunities for development and integration of the industry to accelerate Meihua’s transition from women and children services to women’s full life cycle. Health care, and business extension of family health services. In addition, Dehong will also work closely with the Meihua team to inject new vitality into the company, accelerate the endogenous and extensional development of Meihua, and provide customers with more and better quality medical care Serve.”

Founded in 2003, Meihua Medical is a pioneer and leader in the private high-end medical service industry in Shanghai and even the whole country. Since its establishment 19 years ago, Meihua Medical has adhered to the customer-centric service concept, and has served more than 100,000 families, accumulating an excellent reputation and a loyal customer base. At present, the company has three institutions: Shanghai Meihua Women’s and Children’s Hospital, Shanghai Meihua Lilac Women’s and Children’s Clinic, and Shanghai Ward Medical Center. The business scope covers obstetrics, gynecology, postpartum rehabilitation, pediatrics, family general practice and other fields.

Dehong Capital is an international private equity investment institution focusing on the Asian market. The core team of Dehong Capital has led KKR and Morgan Stanley’s private equity investment business in Asia, and has created long-term excellent investment returns across multiple cycles. Dehong Capital has received strong support from leading international and domestic long-term institutional investors, including sovereign wealth funds, pension funds, endowment funds, funds of funds and family funds in various countries.

In the past 30 years, the Dehong Capital team has invested in a series of pioneering projects in China’s PE industry, and supported many leading Chinese enterprises, such as China Ping An, Mengniu Dairy, Haier, CICC, Oriental Yuhong, Tonghua East Bao, Qiming Medical, Adopt a Cow, Jane Eyre Yogurt, Nanfu Battery, COFCO Meat, Sunnong Development, Far East Horizon, Haoyun Changsheng, Hengan Group, Belle International, Modern Dairy, United Environment, etc. With its international investment experience and localized resource network, Dehong Capital has accumulated profound industry expertise and solid post-investment management capabilities. Adhering to the concept of value investment, Dehong Capital aims to establish a long-term win-win partnership with the invested companies and create value for the long-term development of the invested companies.